Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|September 3, 2026

The Ron Lanton Report: What Are We Doing This All For?

Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, joins Ron Lanton to argue that biopharmaceutical policy only makes sense when traced back to its purpose.

This episode of The Ron Lanton Report closes out season one by asking the question sitting underneath every prior conversation about trade, innovation, and drug pricing: why are we doing any of this in the first place?

Framing the discussion around what she calls the "prize, not price" of innovation, Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, argues that biopharmaceutical policy only makes sense when it is traced back to its purpose, giving people, not an abstract patient population, solutions to problems that would otherwise define or end their lives. Ron Lanton frames this as the natural capstone to a season spent examining innovation, trade, and pricing issue by issue, without ever stepping back to ask what all of it is for.

The episode reframes affordability not as a single problem to be solved but as a question of timing. Whittington points to the biotech social contract, a concept she credits to Dr. Peter Kolchinsky, in which market-based pricing during a patent-protected exclusivity period is meant to be followed by timely generic or biosimilar entry that drops prices toward the marginal cost of production. Both she and Lanton note that prescription drug prices just recorded their steepest annual decline since 1963, evidence in Whittington's view, that this two-phase system works when it is allowed to play out, even as newer interventions like most-favored-nation pricing and direct-to-consumer pricing remain harder to credit directly, given the absence of anything like a controlled comparison.

The analysis then extends into Whittington's own field of Pharmacoeconomics, where she argues the standard tools for valuing innovation have a significant blind spot: time. Cost-effectiveness models typically anchor on a patient starting treatment at launch and assume that launch price holds constant over that patient's lifetime. In reality, prices move throughout a product's life cycle, like Sovaldi which launched near $80,000 and has already fallen to roughly $10,000 to $15,000 through brand-to-brand competition alone, before any generic has entered. That gap between modeling a patient's lifetime at launch price and modeling a product's full lifecycle, she argues, creates a deeper disconnect between what a model calls an "efficient" price and what actually constitutes an optimal reward for innovation.

Finally, the episode turns to where this constraint goes next. Whittington points to the biosimilar market and cell and gene therapy as the coming test case: small-molecule generics have proven they can deliver steep, fast price declines, but biosimilars have not yet shown the same, even as biologics make up a growing share of the pipeline. She also flags the mismatch between policymakers' and insurers' short, budget-cycle decision windows and the long product lifecycles that innovation actually plays out over, arguing that the only way through is to lean harder on evidence-based, historical-pattern assumptions rather than launch-year snapshots.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.